← Back to Search

Checkpoint Inhibitor

Treatment (bintrafusp alfa, SBRT) for Head and Neck Squamous Cell Carcinoma

Phase 1 & 2
Waitlist Available
Led By Renata Ferrarotto
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

Study Summary

This trial is studying bintrafusp alfa and stereotactic body radiation therapy to see how well they work in treating patients with recurrent or second primary head and neck squamous cell cancer.

Eligible Conditions
  • Head and Neck Squamous Cell Carcinoma
  • Squamous Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-free survival (PFS)
Secondary outcome measures
Distant metastases rate
Fibrosis-related functional outcomes
Fibrosis-related toxicities
+9 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (bintrafusp alfa, SBRT)Experimental Treatment4 Interventions
Patients receive bintrafusp alfa IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 15 of cycle 1, patients also undergo SBRT over 5 fractions once QOD for 2 weeks in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stereotactic Body Radiation Therapy
2012
Completed Phase 2
~780
Bintrafusp Alfa
2021
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,639 Previous Clinical Trials
40,930,481 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
2,965 Previous Clinical Trials
1,804,916 Total Patients Enrolled
Renata FerrarottoPrincipal InvestigatorM.D. Anderson Cancer Center
6 Previous Clinical Trials
166 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Current Opinion in OncologyJournal
The Role of the Tumor Matrix Environment in Progression of Head and Neck Cancer
Saint, Angélique, and Ellen Van Obberghen-Schilling. 2021. “The Role of the Tumor Matrix Environment in Progression of Head and Neck Cancer”. Current Opinion in Oncology. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/cco.0000000000000730.
clinicaltrials.govStudy
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
2020. "Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04220775.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top